Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization. Expected FDA clinical and commercial supply in H2-2022. Unlocking potential partnership opportunities with research labs, clinics and pharmaceutical companies globally. TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or…


Previous articleFirst Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Next articleNuminus Advances Phase 1 Trial on Proprietary Psilocybin Product